High-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary prevention.
about
Mechanistically identified suitable biomarkers of exposure, effect, and susceptibility for silicosis and coal-worker's pneumoconiosis: A comprehensive reviewRosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspectiveStatin therapy in metabolic syndrome and hypertension post-JUPITER: what is the value of CRP?Homocysteine and reactive oxygen species in metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy: the pleiotropic effects of folate supplementationAdiponectin as a potential biomarker of vascular diseaseRelationship of adipocyte size with adiposity and metabolic risk factors in Asian IndiansA high sensitivity assay for the inflammatory marker C-Reactive protein employing acoustic biosensing.A Smartphone-Based Colorimetric Reader for Human C-Reactive Protein Immunoassay.Change in growth differentiation factor 15, but not C-reactive protein, independently predicts major cardiac events in patients with non-ST elevation acute coronary syndrome.Stress, age, and immune function: toward a lifespan approach.Short duration of sleep is associated with elevated high-sensitivity C-reactive protein level in Taiwanese adults: a cross-sectional study.A cluster randomised school-based lifestyle intervention programme for the prevention of childhood obesity and related early cardiovascular disease (JuvenTUM 3)Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey.Screening low-risk individuals for coronary artery disease.Psoriasis and vascular disease-risk factors and outcomes: a systematic review of the literatureThe impact of diurnal fasting during Ramadan on the lipid profile, hs-CRP, and serum leptin in stable cardiac patientsPrevention and treatment of the metabolic syndrome.Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on high-sensitivity C-reactive protein levels.Therapeutic administration of the direct thrombin inhibitor argatroban reduces hepatic inflammation in mice with established fatty liver disease.The role of HMG-CoA reductase inhibition in endothelial dysfunction and inflammation.Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease.Adiponectin as an anti-inflammatory factor.Does using ethnic specific criteria improve the usefulness of the term metabolic syndrome? Controversies and suggestions.Clinical implications of C-reactive protein as a predictor of vascular risk.Predictors of vitamin B6 and folate concentrations in older persons: the InCHIANTI study.Oxidative stress biomarkers and lifestyles in Japanese healthy people.Acute phase reactants as novel predictors of cardiovascular disease.Seasonal and sex variation of high-sensitivity C-reactive protein in healthy adults: a longitudinal study.Effect of a Probiotic Preparation (VSL#3) on CardiovascularRisk Parameters in Critically-Ill Patients.Measures of chronic conditions and diseases associated with aging in the national social life, health, and aging project.The use of dried blood spot sampling in the national social life, health, and aging project.Vascular Inflammation: A Novel Access Route for NanomedicinePredictors of improvement in cardiometabolic risk factors with weight loss in women.Obesity, inflammation, and cardiovascular risk.High sensitivity C-reactive protein (Hs-CRP) remains highly stable in long-term archived human serum.Cardiovascular disease, SCI and exercise: unique risks and focused countermeasures.Ability of vitamin D to reduce inflammation in adults without acute illness.Reassessing lipid metabolism and its potentialities in the prediction of cardiovascular risk.The effect of exercise interventions on inflammatory biomarkers in healthy, physically inactive subjects: a systematic review.Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events.
P2860
Q23917334-338FA8EE-655D-4533-B86B-4163ACABE34AQ24594814-A80CD64C-9EA8-45EC-B584-3DFFA74D1F40Q24602803-188EBF13-BE49-433D-8FC6-996D936DC022Q24791545-334CCE63-6B96-4645-83A2-E9BBF75C0AB3Q26821925-5CF04CD4-7568-4C58-BED5-FF14CAB65441Q28543198-09483832-36DF-4669-9CF7-A11DEE1083D7Q30494320-93615088-33CB-4217-8C65-D873F67D2059Q33453332-B25401D2-E9E7-4D49-8143-08AE492099E9Q33563146-C7718A4A-05F5-4B28-A52A-BE18EAFA542EQ33585009-74EEFFC3-BC5B-469F-992D-9AEA78FAE913Q33793996-E9740DED-5661-4659-A6A8-7EDA446D2E1AQ33879837-A0C83DA1-C80F-4BF6-B14C-4398303325DEQ33972551-C49C26DF-EAC6-454D-AA89-7E06F78983F4Q34403960-ED5E7FC8-ED3D-44BE-9721-E64F5C597C53Q35168945-30180F70-B331-485C-B07A-100FB37D42FEQ35684185-1DB78159-2AEB-4027-B136-9F713A32C685Q35952447-6D11FDDD-CF3E-486E-B93D-2495E0707A37Q36268387-E3664A12-1E44-48B1-825B-E39E2F3F5142Q36295444-E97D3F63-E8BA-4CD1-AF02-205F462B9CCAQ36536154-48F04E40-FA4F-4519-8E50-061683A8D571Q36593266-64A31CCE-577E-4054-8058-525D9CF6A626Q36753830-D8D417F4-BF59-4441-A444-ADF25E5794ADQ36793612-9659D49B-26D7-471D-A893-0CBEBEA91C96Q36903050-10687C93-4215-46F8-B221-1166832F2790Q37104249-8F28E861-E1B4-40DD-9D4F-95B0303913CFQ37125388-88DF611C-4493-4EEB-8AE6-BA1BAC23EB57Q37156874-61D202F0-9351-4413-BB84-4ECEAC77C432Q37252436-5B13D5D9-FC78-4020-9847-6045E76376BBQ37301733-7BE56D5F-B9DC-4856-B1C4-11D454598F4AQ37390951-985DBA2D-903D-45C5-9BCC-40ABC4FABF2DQ37390955-A14E823A-01B2-44EB-A58D-4147C20C1E74Q37397963-88C81B9E-BAC3-42F3-9EB3-F9A3CE646286Q37457793-AA36298C-72EB-4151-9CAF-73764124F0D0Q37702091-CD3509BF-ADDD-4958-A45F-F5BF35A48519Q37709537-C62697BD-F174-4EA2-8347-58B6FB2378A3Q37762838-17976212-1F51-48EF-8C38-D68D0DFC3E65Q38170548-248579EC-23C3-4557-A92D-4B89F0A24F98Q38494149-767E8512-3748-4071-B100-EA46AEE2C22DQ39284064-FE6F52AD-F50E-4961-9211-4B6CA42EC5F9Q40461525-479C8A59-09DF-448B-8556-C60DF56EB38B
P2860
High-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary prevention.
description
2003 nî lūn-bûn
@nan
2003 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
High-sensitivity C-reactive pr ...... eening and primary prevention.
@ast
High-sensitivity C-reactive pr ...... eening and primary prevention.
@en
type
label
High-sensitivity C-reactive pr ...... eening and primary prevention.
@ast
High-sensitivity C-reactive pr ...... eening and primary prevention.
@en
prefLabel
High-sensitivity C-reactive pr ...... eening and primary prevention.
@ast
High-sensitivity C-reactive pr ...... eening and primary prevention.
@en
P1476
High-sensitivity C-reactive pr ...... eening and primary prevention.
@en
P2093
Paul M Ridker
P304
P356
10.1016/S0002-9149(03)00774-4
P407
P577
2003-08-01T00:00:00Z